The EHC is excited to have signed a new partnership with the European Patients’ Academy of Therapeutic Innovation (EUPATI).

EUPATI is a non-profit foundation with a multi-stakeholder structure that provides patients and the public with accessible, well-structured, and reliable education about the lifecycle of medicines research and development, while also upskilling professionals on meaningful patient involvement.

The EHC represents approximately 120.000 people diagnosed with rare bleeding conditions such as haemophilia, von Willebrand Disease (VWD), and other extremely rare bleeding disorders. The EHC draws on the knowledge of patients, healthcare professionals, the scientific community, the European institutions, and the pharmaceutical industry to share expertise within Europe. The EHC also collaborates closely with other European patient organisations to ensure a strong collective voice for people with rare bleeding disorders.

This partnership aligns with both organisations’ vision and mission to provide education, information and opportunities for collaboration for patients and the scientific community to support a better health ecosystem. Both organisations operate in a multi-stakeholder structure, making the union a natural fit.